VASH2 increased the expression of ZEB1/2 in pancreatic tumors through activation of the SHH pathway, which both facilitated the EMT process and increased the resistance of pancreatic tumors to gemcitabine chemotherapy23. This evidence concerns the gene SHH and pancreatic neoplasm.